全文获取类型
收费全文 | 1790篇 |
免费 | 302篇 |
国内免费 | 39篇 |
专业分类
耳鼻咽喉 | 13篇 |
儿科学 | 104篇 |
妇产科学 | 20篇 |
基础医学 | 96篇 |
口腔科学 | 28篇 |
临床医学 | 297篇 |
内科学 | 594篇 |
皮肤病学 | 60篇 |
神经病学 | 202篇 |
特种医学 | 280篇 |
外科学 | 203篇 |
综合类 | 31篇 |
预防医学 | 57篇 |
眼科学 | 16篇 |
药学 | 59篇 |
中国医学 | 1篇 |
肿瘤学 | 70篇 |
出版年
2023年 | 53篇 |
2022年 | 12篇 |
2021年 | 30篇 |
2020年 | 90篇 |
2019年 | 13篇 |
2018年 | 90篇 |
2017年 | 72篇 |
2016年 | 72篇 |
2015年 | 65篇 |
2014年 | 95篇 |
2013年 | 114篇 |
2012年 | 52篇 |
2011年 | 44篇 |
2010年 | 78篇 |
2009年 | 110篇 |
2008年 | 53篇 |
2007年 | 50篇 |
2006年 | 44篇 |
2005年 | 33篇 |
2004年 | 16篇 |
2003年 | 12篇 |
2002年 | 19篇 |
2001年 | 31篇 |
2000年 | 14篇 |
1999年 | 29篇 |
1998年 | 81篇 |
1997年 | 98篇 |
1996年 | 79篇 |
1995年 | 68篇 |
1994年 | 50篇 |
1993年 | 53篇 |
1992年 | 29篇 |
1991年 | 15篇 |
1990年 | 29篇 |
1989年 | 53篇 |
1988年 | 45篇 |
1987年 | 28篇 |
1986年 | 20篇 |
1985年 | 20篇 |
1984年 | 16篇 |
1983年 | 11篇 |
1982年 | 15篇 |
1981年 | 14篇 |
1980年 | 15篇 |
1979年 | 9篇 |
1978年 | 8篇 |
1977年 | 9篇 |
1976年 | 11篇 |
1975年 | 9篇 |
1971年 | 9篇 |
排序方式: 共有2131条查询结果,搜索用时 187 毫秒
1.
2.
3.
4.
5.
6.
Riccardo Torta Carlotta Berra Luca Binaschi Roberto Borio 《Supportive care in cancer》2007,15(5):539-546
Introduction Amisulpride is a substituted benzamide that, at low doses, selectively blocks D2 and D3 presynaptic dopamine receptors, enhancing
dopaminergic transmission in frontal cortex and limbic areas. Many clinical studies versus placebo, tricyclic antidepressants
and selective serotonin reuptake inhibitors showed amisulpride antidepressant effect, supporting its safety and rapid onset
of action. In oncological population, depression is quite frequent and difficult to treat because of the particular sensitivity
of cancer patients to the antidepressants’ side effects.
Goals of work The aims of this study were to evaluate efficacy, safety and tolerability of low doses of amisulpride (50 mg) in oncological,
depressed patients during chemotheraphy.
Materials and methods One hundred six consecutive cancer outpatients with depressive symptoms were treated in a prospective, intention to treat,
4-week study, and were evaluated in single-blind with Montgomery Asberg rating scale for depression (MADRS), clinical global
impression (CGI) and dosage record treatment emergent symptom scale (DOTES) to assess side effects of treatment.
Main results After 4 weeks of treatment, scores of MADRS and CGI significantly improved (p < 0.002; p < 0.001, respectively), with a reduction of depressive symptoms concerning both emotional (such as apparent sadness, reported
sadness, inner tension, etc.) and physical cluster (such as lack of appetite, reduction in weight, tiredness and insomnia)
with good tolerability (only two patients dropped out).
Conclusions This study is the first trial on the use of amisulpride in a cohort of oncological, depressed patients during chemotherapy.
Amisulpride demonstrated high efficacy and safety. Controlled studies are needed to confirm these preliminary data. 相似文献
7.
8.
9.
10.
Gross cystic disease of the breast (GCD) is rarely seen after the menopause. Recent work has shown that by measuring electrolytes in the breast cyst fluid (BCF) it is possible to identify two principal classes of cyst, designated Type 1 (K+/Na+ greater than 1.5) and Type 2 (K+/Na+ less than 0.66). A smaller, intermediate class (Type 3) also appears to exist. We measured K+, Na+ and dehydroepiandrosterone sulphate (DHA-S) in 38 BCF samples aspirated from 33 women with GCD who had undergone spontaneous menopause at least 1 yr previously. Statistically significant correlations were found between DHA-S and cations (positive in relation to K+, P less than 0.001; negative in relation to Na+, P less than 0.001). The distribution of cyst types was shifted with respect to that characteristic of cases that occur at an earlier age: whereas Type 1 cysts predominate in menstruating women, Type 2 cysts proved more numerous in the post-menopausal subjects. The difference was statistically validated (P less than 0.001). The results seem to indicate a sharp reduction in high K+, high DHA-S cysts after the menopause, which may be paralleled by a decrease in the associated apocrine metaplasia. In view of the major biochemical differences between Type 1 and Type 2 cysts and of the suggested differences as regards cancer risk, classification of post-menopausal patients with GCD by cyst type is critical prior to any clinical trial or follow-up. 相似文献